CL2018000829A1 - Anticuerpos anti-cd19 humano con alta afinidad - Google Patents

Anticuerpos anti-cd19 humano con alta afinidad

Info

Publication number
CL2018000829A1
CL2018000829A1 CL2018000829A CL2018000829A CL2018000829A1 CL 2018000829 A1 CL2018000829 A1 CL 2018000829A1 CL 2018000829 A CL2018000829 A CL 2018000829A CL 2018000829 A CL2018000829 A CL 2018000829A CL 2018000829 A1 CL2018000829 A1 CL 2018000829A1
Authority
CL
Chile
Prior art keywords
antibodies
human anti
high affinity
methods
human
Prior art date
Application number
CL2018000829A
Other languages
English (en)
Inventor
Ekkehard Moessner
Koller Claudia Ferrara
Thomas Hofer
Mi He
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2018000829A1 publication Critical patent/CL2018000829A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se refiere a anticuerpos contra CD19 humano (anticuerpos anti-CD19 humano), métodos para su producción, composiciones farmacéuticas que contienen estos anticuerpos, y métodos de uso de los mismos.
CL2018000829A 2015-10-02 2018-03-29 Anticuerpos anti-cd19 humano con alta afinidad CL2018000829A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15188262 2015-10-02
EP16167893 2016-05-02

Publications (1)

Publication Number Publication Date
CL2018000829A1 true CL2018000829A1 (es) 2019-05-03

Family

ID=57042875

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000829A CL2018000829A1 (es) 2015-10-02 2018-03-29 Anticuerpos anti-cd19 humano con alta afinidad

Country Status (23)

Country Link
US (3) US20180230215A1 (es)
EP (1) EP3356405A1 (es)
JP (1) JP6918789B2 (es)
KR (1) KR20180054863A (es)
CN (1) CN108137698B (es)
AU (1) AU2016330807B2 (es)
BR (1) BR112018006350A2 (es)
CA (1) CA3000045C (es)
CL (1) CL2018000829A1 (es)
CO (1) CO2018004532A2 (es)
CR (1) CR20180175A (es)
HK (1) HK1256366A1 (es)
IL (1) IL258271B (es)
MA (1) MA43019A (es)
MX (1) MX2018003827A (es)
MY (1) MY193249A (es)
PE (1) PE20181089A1 (es)
PH (1) PH12018500707A1 (es)
RU (1) RU2761077C1 (es)
TW (1) TWI748964B (es)
UA (1) UA125685C2 (es)
WO (1) WO2017055328A1 (es)
ZA (1) ZA201801993B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049982T2 (hu) 2014-11-14 2020-11-30 Hoffmann La Roche TNF-családba tartozó ligandum-trimert tartalmazó antigénkötõ molekulák
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US20180064758A1 (en) * 2016-09-05 2018-03-08 Ucl Business Plc Chimeric antigen receptor
WO2018114748A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
TW201829469A (zh) 2017-01-03 2018-08-16 瑞士商赫孚孟拉羅股份公司 包含抗4-1bb純系20h4.9之雙特異性抗原結合分子
EP3601345A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
KR20200055758A (ko) * 2017-09-21 2020-05-21 우시 바이올로직스 아일랜드 리미티드 신규 항-cd19 항체
CN111246884A (zh) 2017-11-01 2020-06-05 豪夫迈·罗氏有限公司 新颖的含有tnf家族配体三聚体的抗原结合分子
EP3723788A4 (en) * 2017-12-15 2022-04-13 Aleta Biotherapeutics Inc. CD19 VARIANTS
CN108047332B (zh) * 2018-01-15 2021-08-24 阿思科力(苏州)生物科技有限公司 以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
TW202035447A (zh) 2018-07-04 2020-10-01 瑞士商赫孚孟拉羅股份公司 新穎雙特異性促效性4-1bb抗原結合分子
MX2021003548A (es) 2018-10-01 2021-05-27 Hoffmann La Roche Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap.
CN113286821A (zh) 2018-12-21 2021-08-20 豪夫迈·罗氏有限公司 靶向肿瘤的激动性cd28抗原结合分子
WO2020177992A1 (en) 2019-03-01 2020-09-10 Universität Für Bodenkultur Wien Stabilized extracellular domain of cd19
US20220347298A1 (en) 2019-10-04 2022-11-03 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
CA3161411A1 (en) * 2019-12-11 2021-06-17 Cullinan Management, Inc. Anti-serum albumin antibodies
US20230037815A1 (en) * 2019-12-11 2023-02-09 Cullinan Oncology, Inc. Anti-cd19 antibodies and multi-specific binding proteins
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
TWI811703B (zh) 2020-06-19 2023-08-11 瑞士商赫孚孟拉羅股份公司 與ｃｄ３及ｃｄ１９結合之抗體
EP4240491A1 (en) * 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1314741B1 (en) * 2001-11-14 2007-03-07 Affimed Therapeutics AG Bispecific anti-CD19 x anti-CD16 antibodies and uses thereof
AU2006214121B9 (en) * 2005-02-15 2013-02-14 Duke University Anti-CD19 antibodies and uses in oncology
CN101233156B (zh) * 2005-06-20 2012-06-27 米德列斯公司 Cd19抗体及其用途
RS53263B (en) * 2006-08-14 2014-08-29 Xencor Inc. CD19 OPTIMIZED ANTIBODY
US8323653B2 (en) * 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2011147834A1 (en) * 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409993A1 (en) * 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
WO2012130831A1 (en) * 2011-03-29 2012-10-04 Roche Glycart Ag Antibody fc variants
HUE049982T2 (hu) * 2014-11-14 2020-11-30 Hoffmann La Roche TNF-családba tartozó ligandum-trimert tartalmazó antigénkötõ molekulák
EP3277305B1 (en) * 2015-03-31 2021-07-21 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand

Also Published As

Publication number Publication date
CA3000045C (en) 2024-01-02
KR20180054863A (ko) 2018-05-24
EP3356405A1 (en) 2018-08-08
PH12018500707A1 (en) 2018-10-15
HK1256366A1 (zh) 2019-09-20
US20200317774A1 (en) 2020-10-08
RU2761077C1 (ru) 2021-12-03
WO2017055328A1 (en) 2017-04-06
ZA201801993B (en) 2019-01-30
JP6918789B2 (ja) 2021-08-11
MA43019A (fr) 2018-08-08
TWI748964B (zh) 2021-12-11
UA125685C2 (uk) 2022-05-18
MX2018003827A (es) 2018-06-22
JP2018535657A (ja) 2018-12-06
IL258271A (en) 2018-05-31
PE20181089A1 (es) 2018-07-09
IL258271B (en) 2022-05-01
MY193249A (en) 2022-09-28
CN108137698A (zh) 2018-06-08
CO2018004532A2 (es) 2018-11-22
AU2016330807A1 (en) 2018-04-12
US20180230215A1 (en) 2018-08-16
TW201718654A (zh) 2017-06-01
CN108137698B (zh) 2022-04-19
US20230312710A1 (en) 2023-10-05
CA3000045A1 (en) 2017-04-06
BR112018006350A2 (pt) 2018-10-09
CR20180175A (es) 2018-05-03
AU2016330807B2 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
CL2018000106A1 (es) Moléculas de anticuerpo que se unen a cd45
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
CL2018000819A1 (es) Anticuerpos biespecíficos anti-cd20 humano/receptor de transferrina humano y métodos para su uso
DOP2017000298A (es) Reguladores de nrf2
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
CR20180605A (es) Anticuerpos anti-cd40 y sus usos
ECSP17045736A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
CO2019009787A2 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
CO2019013718A2 (es) Anticuerpos anti-trkb